1. Home
  2. PDO vs SUPN Comparison

PDO vs SUPN Comparison

Compare PDO & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PDO
  • SUPN
  • Stock Information
  • Founded
  • PDO 2020
  • SUPN 2005
  • Country
  • PDO United States
  • SUPN United States
  • Employees
  • PDO N/A
  • SUPN N/A
  • Industry
  • PDO Trusts Except Educational Religious and Charitable
  • SUPN Biotechnology: Pharmaceutical Preparations
  • Sector
  • PDO Finance
  • SUPN Health Care
  • Exchange
  • PDO Nasdaq
  • SUPN Nasdaq
  • Market Cap
  • PDO 1.7B
  • SUPN 1.7B
  • IPO Year
  • PDO N/A
  • SUPN 2012
  • Fundamental
  • Price
  • PDO $12.94
  • SUPN $32.98
  • Analyst Decision
  • PDO
  • SUPN Hold
  • Analyst Count
  • PDO 0
  • SUPN 2
  • Target Price
  • PDO N/A
  • SUPN $36.00
  • AVG Volume (30 Days)
  • PDO 520.0K
  • SUPN 646.7K
  • Earning Date
  • PDO 01-01-0001
  • SUPN 05-07-2025
  • Dividend Yield
  • PDO 11.80%
  • SUPN N/A
  • EPS Growth
  • PDO N/A
  • SUPN 6500.00
  • EPS
  • PDO N/A
  • SUPN 1.32
  • Revenue
  • PDO N/A
  • SUPN $661,817,000.00
  • Revenue This Year
  • PDO N/A
  • SUPN N/A
  • Revenue Next Year
  • PDO N/A
  • SUPN $9.32
  • P/E Ratio
  • PDO N/A
  • SUPN $24.86
  • Revenue Growth
  • PDO N/A
  • SUPN 8.94
  • 52 Week Low
  • PDO $10.65
  • SUPN $25.53
  • 52 Week High
  • PDO $13.31
  • SUPN $40.28
  • Technical
  • Relative Strength Index (RSI)
  • PDO 28.34
  • SUPN 46.25
  • Support Level
  • PDO $13.72
  • SUPN $31.13
  • Resistance Level
  • PDO $13.94
  • SUPN $32.93
  • Average True Range (ATR)
  • PDO 0.12
  • SUPN 1.00
  • MACD
  • PDO -0.02
  • SUPN 0.19
  • Stochastic Oscillator
  • PDO 18.75
  • SUPN 50.06

About PDO PIMCO Dynamic Income Opportunities Fund of Beneficial Interest

PIMCO Dynamic Income Opportunities Fund is a closed-end management investment company. The fund's primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities.

About SUPN Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

Share on Social Networks: